NCT05497843View on ClinicalTrials.gov

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

January 3, 2025

Study Completion Date

January 3, 2025

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Chiauranib

50mg, orally once daily

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY

NCT05497843 - Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) | Biotech Hunter | Biotech Hunter